The Women's Longevity Gap: Why Medicine Has Been Getting Female Health Wrong for Decades

The Global Wellness Summit's 2026 report identifies 'ovary-span' as the key to women's healthspan. Here is the science behind why women's longevity has been systematically under-researched.

The observation that medical research has systematically excluded or underrepresented women in clinical trials is not new — it has been documented and critiqued for thirty years since the NIH Revitalization Act of 1993 required women's inclusion in federally funded clinical research. What is new in 2026 is the specific framework emerging from women's health research that identifies ovarian aging as the central biological mechanism whose understanding could transform health outcomes for women across their entire lifespan.

The concept of 'ovary-span' — the length and quality of the period during which the ovaries maintain functional hormonal output — is being positioned by researchers as the primary determinant of women's healthspan in ways that have not previously been operationalised in clinical practice. The ovaries are not merely the organs of reproduction; they are endocrine organs whose hormonal output — oestrogen, progesterone, and a suite of other hormones that regulate bone density, cardiovascular function, brain health, immune function, and metabolic rate — fundamentally affects the function of virtually every body system.

When the ovaries' hormonal output declines at menopause, typically between ages 45 and 55, the withdrawal of these hormones produces effects that extend far beyond the hot flashes and mood changes that popular culture associates with menopause. Accelerated bone density loss, increased cardiovascular risk, increased Alzheimer's risk, and the specific metabolic shift toward abdominal fat accumulation are all hormonally mediated consequences of menopause that affect quality and length of life.

Hormone replacement therapy's status has oscillated dramatically based on a single flawed study — the Women's Health Initiative trial — that used synthetic progestins rather than bioidentical progesterone and studied women who began HRT significantly after their menopause transition rather than at its onset. The 'timing hypothesis' — that HRT initiated early in the menopause transition provides cardiovascular and cognitive protection while HRT initiated late does not — has been supported by subsequent research and is reshaping clinical practice, with 2026 seeing accelerating prescription rates of bioidentical hormone therapy in the early perimenopausal period.

For younger women: the wellness market is beginning to offer ovarian reserve testing — assessments of how many viable eggs remain and, by extension, how far through the biological clock the individual woman has progressed — as a wellness metric rather than a fertility metric. Using this information to guide preventive health investment decades before menopause is the specific clinical innovation that the 'ovary-span' framework predicts will define women's preventive medicine in the 2030s.